Synthetic Cannabinoid Innovations: Nalu Bio Secures $12 Million in Series A Funding
In a significant stride towards revolutionizing cannabinoid production for safer consumer products, Nalu Bio, a San Francisco-based synthetic cannabinoids producer, successfully raised $12 million in a Series A funding round. The investment was led by Intrinsic Capital Partners, a Pennsylvania-based investment firm with a focus on life science and technology businesses in the legal marijuana and hemp industries. The funding, which was announced in a news release on Tuesday, arrives at a critical juncture in the hemp and marijuana sectors, where raising capital has been challenging due to scarcity of deals and expensive terms.
Moreover, the regulatory landscape surrounding cannabinoids is becoming more stringent, with states like Connecticut, Virginia, and Utah cracking down on the production and sale of delta-8 products and their derivatives. In response to these challenges, lawmakers in West Virginia are even considering a ban on products containing delta-8 THC.
The Series A funding round saw support from multiple backers, including Flybridge Capital Partners, Portfolia Active Aging & Longevity Fund, Bonaventure Equity, L37 Ventures, Golden Seeds, Sacramento Angels, Brown Angel Group, and Axial Venture. This strong financial backing is expected to bolster Nalu Bio’s growth and enable the scaling of cannabinoid production for consumer products and therapeutics. Particularly noteworthy is Nalu Bio’s specialization in the synthesis of the nonpsychoactive, minor cannabinoid THCV, utilizing a cost-effective method.
CEO and co-founder of Nalu Bio, Caitlyn Krebs, stated, “At Nalu Bio, we have created a platform that produces ultra-pure, cost-effective, non-hemp derived cannabinoids so that consumers and companies will have safer, more reliable products that improve everyday life.” The company’s mission is to provide high-quality cannabinoids to manufacturers seeking cost-effective THC-free ingredients, expanding their reach worldwide and establishing themselves as category leaders.
One key differentiator for Nalu Bio lies in its groundbreaking production technique, which relies on organic, non-hemp compounds to generate desired cannabinoid ingredients. By doing so, the company achieves “molecularly identical versions of naturally occurring cannabinoids,” completely free from the contaminants sometimes found in hemp-extracted cannabinoids.
In the pipeline are plans to launch a full suite of cannabinoid-like products, imitating CBD, THCV, CBN, CBC, CBG, among others. As global demand surges, Nalu Bio is gearing up to expand its scientific and commercial teams to meet the needs of consumers and manufacturers alike.
With the infusion of $12 million in funding and its innovative approach to synthetic cannabinoid production, Nalu Bio is poised to reshape the cannabinoid industry, paving the way for safer and more reliable consumer products. As the company continues to make strides in its research and development, the future of cannabinoids looks promising, and Nalu Bio stands ready to lead the charge in Synthetic Cannabinoid Innovations.
